

# Seong Yong Lim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1484430/publications.pdf>

Version: 2024-02-01

43  
papers

941  
citations

516710

16  
h-index

454955

30  
g-index

43  
all docs

43  
docs citations

43  
times ranked

1531  
citing authors

#	ARTICLE	IF	CITATIONS
1	Korean physician prescription patterns for home oxygen therapy in chronic obstructive pulmonary disease patients. Korean Journal of Internal Medicine, 2022, 37, 119-126.	1.7	2
2	Direct Switch from Tiotropium to Indacaterol/Glycopyrronium in Chronic Obstructive Pulmonary Disease Patients in Korea. Tuberculosis and Respiratory Diseases, 2021, 84, 96-104.	1.8	3
3	Predicting long-term mortality with two different criteria of exercise-induced desaturation in COPD. Respiratory Medicine, 2021, 182, 106393.	2.9	6
4	Korean Clinical Imaging Guidelines for the Appropriate Use of Chest MRI. Journal of the Korean Society of Radiology, 2021, 82, 562.	0.2	0
5	Severe vitamin D deficiency is associated with emphysema progression in male patients with COPD. Respiratory Medicine, 2020, 163, 105890.	2.9	6
6	The health-related quality-of-life of chronic obstructive pulmonary disease patients and disease-related indirect burdens. Korean Journal of Internal Medicine, 2020, 35, 1136-1144.	1.7	7
7	Hyperuricemia Is Not Predictive of Long-Term Outcome in Patients with Stable Chronic Obstructive Pulmonary Disease. Journal of Korean Medical Science, 2020, 35, e58.	2.5	1
8	Current Situation of Home Oxygen Therapy for Chronic Obstructive Pulmonary Disease Patients in Korea. Journal of Korean Medical Science, 2020, 35, e12.	2.5	3
9	&lt;p&gt;Risk of chronic obstructive pulmonary disease in healthy individuals with high C-reactive protein levels by smoking status: a population-based cohort study in Korea&lt;/p&gt;. International Journal of COPD, 2019, Volume 14, 2037-2046.	2.3	3
10	The Economic Effect of Early Management in Patients with Early Chronic Obstructive Pulmonary Disease: Results from a Population-Based Nationwide Survey. Lung, 2019, 197, 303-313.	3.3	5
11	Acute Exacerbation According to GOLD 2017 Categories in Patients with Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2019, 55, 414-420.	0.8	11
12	&lt;p&gt;Metabolic Syndrome in Early Chronic Obstructive Pulmonary Disease: Gender Differences and Impact on Exacerbation and Medical Costs&lt;/p&gt;. International Journal of COPD, 2019, Volume 14, 2873-2883.	2.3	24
13	<p>Mixed Phenotype of Emphysema and Airway Wall Thickening Is Associated with Frequent Exacerbation in Chronic Obstructive Pulmonary Disease Patients</p>. International Journal of COPD, 2019, Volume 14, 3035-3042.	2.3	12
14	Direct and Indirect Costs of Chronic Obstructive Pulmonary Disease in Korea. Tuberculosis and Respiratory Diseases, 2019, 82, 27.	1.8	28
15	Validation of Previous Spirometric Reference Equations and New Equations. Journal of Korean Medical Science, 2019, 34, e304.	2.5	15
16	Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort. Respiratory Research, 2018, 19, 36.	3.6	23
17	Urinary desmosine is associated with emphysema severity and frequent exacerbation in patients with <sc>COPD</sc>. Respirology, 2018, 23, 176-181.	2.3	10
18	Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary. Tuberculosis and Respiratory Diseases, 2018, 81, 261.	1.8	32

#	ARTICLE	IF	CITATIONS
19	Which GOLD B patients progress to GOLD D with the new classification?. International Journal of COPD, 2018, Volume 13, 3233-3241.	2.3	2
20	Blood eosinophil count as a prognostic biomarker in COPD. International Journal of COPD, 2018, Volume 13, 3589-3596.	2.3	23
21	Treatment and prevention of acute exacerbation of chronic obstructive pulmonary disease. Journal of the Korean Medical Association, 2018, 61, 552.	0.3	0
22	Development of Prediction Equation of Diffusing Capacity of Lung for Koreans. Tuberculosis and Respiratory Diseases, 2018, 81, 42.	1.8	2
23	Which bronchodilator reversibility criteria can predict severe acute exacerbation in chronic obstructive pulmonary disease patients?. Respiratory Research, 2017, 18, 107.	3.6	7
24	Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. International Journal of COPD, 2017, Volume 12, 2465-2475.	2.3	267
25	Inhaled indacaterol for the treatment of COPD patients with destroyed lung by tuberculosis and moderate-to-severe airflow limitation: results from the randomized INFINITY study. International Journal of COPD, 2017, Volume 12, 1589-1596.	2.3	24
26	Anemia as a clinical marker of stable chronic obstructive pulmonary disease in the Korean obstructive lung disease cohort. Journal of Thoracic Disease, 2017, 9, 5008-5016.	1.4	7
27	Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. International Journal of COPD, 2016, 11, 23.	2.3	23
28	Implications of Emphysema and Lung Function for the Development of Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases, 2016, 79, 91.	1.8	5
29	Combination therapy of inhaled steroids and long-acting beta2-agonists in asthma&ndash;COPD overlap syndrome. International Journal of COPD, 2016, Volume 11, 2797-2803.	2.3	34
30	The relationship between serum fatty-acid binding protein 4 level and lung function in Korean subjects with normal ventilatory function. BMC Pulmonary Medicine, 2016, 16, 34.	2.0	3
31	Three-month Treatment Response and Exacerbation in Chronic Obstructive Pulmonary Disease. Journal of Korean Medical Science, 2015, 30, 54.	2.5	2
32	Lung function decline rates according to GOLD group in patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 1819.	2.3	48
33	The Prognostic Value of Residual Volume/Total Lung Capacity in Patients with Chronic Obstructive Pulmonary Disease. Journal of Korean Medical Science, 2015, 30, 1459.	2.5	37
34	Association of Plasma Adipokines with Chronic Obstructive Pulmonary Disease Severity and Progression. Annals of the American Thoracic Society, 2015, 12, 1005-1012.	3.2	29
35	Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. Cancer Chemotherapy and Pharmacology, 2015, 76, 933-937.	2.3	3
36	Comparison of Clinical Efficacy and Safety between Indacaterol and Tiotropium in COPD: Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2015, 10, e0119948.	2.5	9

#	ARTICLE	IF	CITATIONS
37	Influence of Environmental Exposures on Patients with Chronic Obstructive Pulmonary Disease in Korea. <i>Tuberculosis and Respiratory Diseases</i> , 2014, 76, 226.	1.8	7
38	Validity of the COPD Assessment Test Translated Into Local Languages for Asian Patients. <i>Chest</i> , 2013, 143, 703-710.	0.8	38
39	Validation of the Lower Limit of Normal Diffusing Capacity for Detecting Emphysema. <i>Respiration</i> , 2011, 81, 287-293.	2.6	11
40	Metabolic Syndrome, Insulin Resistance and Systemic Inflammation as Risk Factors for Reduced Lung Function in Korean Nonsmoking Males. <i>Journal of Korean Medical Science</i> , 2010, 25, 1480.	2.5	44
41	Responses to inhaled long-acting beta-agonist and corticosteroid according to COPD subtype. <i>Respiratory Medicine</i> , 2010, 104, 542-549.	2.9	89
42	Usefulness of open lung biopsy in mechanically ventilated patients with undiagnosed diffuse pulmonary infiltrates: influence of comorbidities and organ dysfunction. <i>Critical Care</i> , 2007, 11, R93.	5.8	35
43	Accuracy of Spirometry at Predicting Restrictive Pulmonary Impairment. <i>Tuberculosis and Respiratory Diseases</i> , 2003, 54, 330.	0.2	1